Life Changing
Cell and Gene Therapies

Our proprietary technologies and therapeutic products are designed to overcome current industry limitations

Regenerative medicine products, through cell and gene therapy, will heal tissues and organs damaged by age, disease or trauma.

Breakthrough Technologies

Our proprietary technologies are designed to overcome limitations with current cell and gene therapies 

IntraStem: is a novel peptide based intracellular delivery (transfection) technology that overcomes key limitations of viral and non-viral delivery systems at present, to deliver improved gene therapies.

TAOS: is a cell delivery system that addresses the major challenge of ensuring that cellular therapies stay at the intended site of action and that they are remain viable in host tissues, so that they can exert their therapeutic effect whilst being safe and well tolerated.(Tm)

Products Pipeline

We are expanding our therapeutic focus beyond our current orthopedic pipeline to include liver, hematology and CNS tissue applications 

Beyond our core focus areas, our technologies have applications in a wide range of therapy areas and approaches, providing opportunities for partner companies. 

Working with leaders in the regenerative medicine field

Locate has a pipeline agreement with the University of Nottingham which provides exclusive access to new technological breakthroughs by Locate’s scientific founder, Professor Kevin Shakesheff, and his world-leading regenerative medicine research team.

Partnering opportunities

Our technologies were invented by world-leading regenerative medicine scientists in the UK and have been developed by Locate over several years. 

IntraStem™ has a broad range of potential applications, including gene therapy and ex vivo cell therapy modification, and offers major advantages over current transfection technologies. Locate is currently evaluating a number of new product opportunities for in-house development and for potential third party collaborations.

Our TAOS® technology has been validated and manufacture established in house under the development of several in-house orthopedic programmes. TAOS can be used in a wide range of other tissue types and therapy areas, supported by promising in vivo data including in the CNS